Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.570
+0.068 (13.51%)
Nov 7, 2024, 4:00 PM EST - Market closed

Company Description

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States.

Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.

Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee’s Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics, Inc.
Unicycive Therapeutics logo
Country United States
Founded 2016
IPO Date Jul 13, 2021
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Shalabh Gupta

Contact Details

Address:
4300 El Camino Real, Suite 210
Los Altos, California 94022
United States
Phone 650 351 4495
Website unicycive.com

Stock Details

Ticker Symbol UNCY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001766140
CUSIP Number 90466Y103
ISIN Number US90466Y1038
Employer ID 81-3638692
SIC Code 2834

Key Executives

Name Position
Dr. Shalabh K. Gupta M.D., MPA Founder, Chairman, Chief Executive Officer and President
Dr. Pramod Gupta Ph.D. Executive Vice President of Pharmaceutical and Business Operations
Douglas Jermasek M.B.A. Executive Vice President of Corporate Strategy
John W. Townsend CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Oct 11, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 25, 2024 8-K Current Report
Aug 14, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Jul 18, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jul 16, 2024 EFFECT Notice of Effectiveness
Jul 16, 2024 424B3 Prospectus
Jul 15, 2024 8-K Current Report
Jul 15, 2024 8-K Current Report
Jul 8, 2024 UPLOAD Filing